糖尿病足 中国就医指南

Diabetic foot is a serious, limb-threatening complication of diabetes mellitus characterized by infection, ulceration, and/or deep tissue destruction in the foot, often occurring in the context of peripheral neuropathy and/or peripheral artery disease. It arises from a complex interplay of metabolic, vascular, neurological, and biomechanical abnormalities. Chronically elevated blood glucose levels damage peripheral nerves (causing sensory, motor, and autonomic neuropathy), impairing protective sensation and foot muscle function—leading to unrecognized trauma and abnormal pressure distribution. Concurrently, hyperglycemia accelerates atherosclerosis and microvascular dysfunction, reducing blood flow to the feet and compromising wound healing and immune defense. Infection—often polymicrobial—can rapidly progress from superficial cellulitis to osteomyelitis or necrotizing fasciitis if untreated. Epidemiologically, diabetic foot ulcers affect approximately 15–25% of people with diabetes over their lifetime; globally, one lower-limb amputation occurs every 30 seconds due to diabetes-related complications. In China, prevalence is rising in parallel with the national diabetes epidemic—estimated at over 140 million adults living with diabetes—and diabetic foot accounts for >60% of non-traumatic lower-limb amputations in endocrinology departments. Key modifiable risk factors include poor glycemic control (HbA1c >8%), smoking, uncontrolled hypertension, dyslipidemia, history of prior foot ulcer or amputation, visual impairment, renal insufficiency, and inadequate footwear or foot hygiene. Non-modifiable risks include longer diabetes duration (>10 years), older age, male sex, and certain genetic predispositions. Beyond physical morbidity, diabetic foot profoundly impairs quality of life: patients report severe pain, mobility limitations, social isolation, depression, anxiety, loss of employment, and caregiver burden. Chronic wounds often necessitate prolonged offloading, frequent clinic visits, and hospitalizations—disrupting daily routines and eroding independence. Psychological distress correlates strongly with ulcer recurrence and delayed healing. Early detection through structured foot screening (monofilament testing, Doppler assessment, dermatological inspection) and multidisciplinary intervention—including endocrinologists, podiatrists, vascular surgeons, infectious disease specialists, and wound care nurses—is critical to prevent progression and preserve limb and life.

# 糖尿病足治疗方案与费用明细（内分泌科）

一、非手术/保守治疗方案

适用人群：Wagner 0–2级、无深部感染、血供尚可、血糖控制达标（HbA1c＜8.0%）者

• •基础管理：血糖监测（指尖血糖×30次）、足部护理教育、减压鞋具定制（RMB 800–3,500）
• •药物治疗：胰岛素强化方案（门冬+地特胰，月均药费 RMB 450–1,200）；抗生素（如哌拉西林他唑巴坦静脉7天，RMB 1,800–3,200）
• •理疗与创面处理：负压引流（VAC）单次 RMB 600–1,500；超声清创（含耗材）RMB 400–900/次；高压氧（10次疗程）RMB 2,800–4,500
• •检查费：下肢动脉超声（RMB 320–480）、糖化血红蛋白（RMB 60）、创面细菌培养+药敏（RMB 180–260）

二、手术与介入治疗方案

适用人群：Wagner 3–4级、局限性坏死、血管狭窄＞70%或存在脓肿/骨髓炎证据者

• •微创清创+骨钻孔术（保留肢体）：RMB 8,500–15,000（含麻醉、住院5–7天）
• •血管腔内介入（PTA/Stent）：单节段 RMB 22,000–38,000；多节段 RMB 35,000–52,000
• •截肢术（趾/前足/中足）：RMB 12,000–28,000（含术后康复评估）
• •术前检查：CTA/MRA（RMB 1,200–2,600）、心肺功能评估（RMB 800–1,500）

三、复杂晚期/耐药并发症方案

Wagner 4–5级合并多重耐药菌、严重缺血或肾衰竭者：个体化MDT联合治疗（内分泌科+血管外科+感染科+康复科），含长期静脉抗生素（替加环素等）、定制外固定架、人工真皮移植，总费用 RMB 65,000–180,000+

四、方案快速选择指南

• •预算＜1万元：优选保守治疗+基层转诊绿色通道
• •保肢意愿强+中度缺血：优先PTA联合VAC（RMB 3万内）
• •危及生命感染/广泛坏死：急诊清创+分期截肢（性价比最高，避免脓毒症死亡）
• •医保患者：90%基础药物、VAC、PTA及截肢术均属医保甲类报销范围